List of Natroba drug patents

Natroba is owned by Parapro Llc.

Natroba contains Spinosad.

Natroba has a total of 2 drug patents out of which 0 drug patents have expired.

Natroba was authorised for market use on 18 January, 2011.

Natroba is available in suspension;topical dosage forms.

Natroba can be used as the product composition (natroba) is for the topical treatment of human scabies mite infestations by melting and delivering the active ingredient, spinosad, to the stratum corneum where scabies mites live and breed, natroba topical suspension is a pediculicide indicated for the topical treatment of head lice infestation in patients six (6) months of age and older..

The generics of Natroba are possible to be released after 25 November, 2033.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6063771 PARAPRO LLC Formulations for controlling human lice
Jul, 2023

(5 months from now)

US9895388 PARAPRO LLC Methods and compositions useful for controlling cutaneous mites
Nov, 2033

(10 years from now)

Exclusivity Exclusivity Expiration
New Indication (I) Apr 28, 2024

Drugs and Companies using SPINOSAD ingredient

Market Authorisation Date: 18 January, 2011

Treatment: Natroba topical suspension is a pediculicide indicated for the topical treatment of head lice infestation in patients six (6) months of age and older.; The product composition (natroba) is for the topical treatment of human scabies mite infestations by melting and delivering the active ingredient, spinosad, to the stratum corneum where scabies mites live and breed

Dosage: SUSPENSION;TOPICAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic